Paragon Capital Management Inc. Sells 49,241 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Paragon Capital Management Inc. cut its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 75.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,402 shares of the biopharmaceutical company’s stock after selling 49,241 shares during the quarter. Paragon Capital Management Inc.’s holdings in Royalty Pharma were worth $464,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swedbank AB acquired a new stake in Royalty Pharma during the first quarter worth approximately $251,461,000. New South Capital Management Inc. bought a new stake in shares of Royalty Pharma during the 1st quarter valued at $44,384,000. Homestead Advisers Corp grew its holdings in shares of Royalty Pharma by 40.7% during the 1st quarter. Homestead Advisers Corp now owns 1,892,540 shares of the biopharmaceutical company’s stock worth $57,502,000 after purchasing an additional 547,000 shares in the last quarter. Dark Forest Capital Management LP increased its position in shares of Royalty Pharma by 2,974.4% in the second quarter. Dark Forest Capital Management LP now owns 338,675 shares of the biopharmaceutical company’s stock worth $8,931,000 after purchasing an additional 327,659 shares during the period. Finally, AQR Capital Management LLC increased its position in shares of Royalty Pharma by 69.0% in the second quarter. AQR Capital Management LLC now owns 785,567 shares of the biopharmaceutical company’s stock worth $20,715,000 after purchasing an additional 320,606 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on RPRX shares. Morgan Stanley increased their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Finally, The Goldman Sachs Group lifted their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.00.

Royalty Pharma Stock Up 1.4 %

RPRX stock opened at $28.22 on Thursday. The firm has a 50-day moving average price of $27.91 and a 200-day moving average price of $27.70. Royalty Pharma plc has a 12 month low of $25.20 and a 12 month high of $31.66. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $16.75 billion, a P/E ratio of 24.97, a price-to-earnings-growth ratio of 4.05 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The business had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. During the same quarter in the prior year, the firm earned $0.85 EPS. As a group, equities research analysts anticipate that Royalty Pharma plc will post 4.04 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 2.98%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is 74.34%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.